Clearmind Medicine Inc. Common Shares
CMNDStock
$1.99−99.53%52W
Market Cap$2.72M
P/E—
Div yield—
Beta19.94
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-102.32%
Price vs S&P 500 (4W)-42.64%
VGM Score5.13
Market Capitalization$2.72M
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CMNDClearmind Medicine Inc. Common Shares | — | — | F | $1.99 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Clearmind Medicine is a clinical-stage biopharmaceutical company developing MEAI, a novel psychedelic compound, for treating mental health disorders including alcohol use disorder, binge drinking, and eating disorders. The company is advancing its lead candidate through Phase I/IIa clinical trials with operations based in Israel.